This week, InfoWars published insider information that alleges the TSA and US Border Patrol will be moving back to 2020-era COVID-19 mandates and restrictions starting in mid-September through mid-October, to include mask mandates on all flights.  This is in addition to the confirmed mask-mandate reinstatement at Morris Brown College in Atlanta, GA and Lionsgate Studios in Santa Monica, CA.

That same week, WarRoom’s Natalie Winters uncovered millions of dollars in funding, awarded primarily for the Department of Veteran’s Affairs, to ramp up testing and other COVID-19 related.  This was just a week after the NIH appointed Dr. Jeanne Marrazzo, a staunch advocate for masks, lockdowns, and vaccine mandates, as the replacement for Dr. Fauci.

To further the suggestion that another lockdown scare is in the forecast, yesterday the US Department of Health and Human Services announced funding of $1.4 billion to “support the development of a new generation of tools and technologies to protect against COVID-19 for years to come” according to a press release:

The awards announced today follow extensive coordination with industry partners and include support for clinical trials that will enable the rapid development of even more effective and longer-lasting coronavirus vaccines, a new monoclonal antibody, and transformative technologies to streamline manufacturing processes.

“Project NextGen is a key part of the Biden-Harris Administration’s commitment to keeping people safe from COVID-19 variants,” said HHS Secretary Xavier Becerra. “These awards are a catalyst for the program – kickstarting efforts to more quickly develop vaccines and continue to ensure availability of effective treatments.”

Project NextGen, a $5 billion initiative led by ASPR’s Biomedical Advanced Research and Development Authority (BARDA) in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), coordinates across the federal government and the private sector to advance innovative vaccines and therapeutics into clinical trials, regulatory review, and potential commercial availability for the American people. The project builds on a better understanding of COVID-19 – with HHS developing, using, and constantly re-evaluating the strengths and weaknesses of current vaccines and therapeutics for over three years.

Recipients of the awards include:

• $1 billion to four BARDA Clinical Trial partners to support vaccine Phase IIb clinical trial studies: ICON Government and Public Health Solutions, Inc of Hinckley, Ohio; Pharm-Olam, LLC, of Houston, Texas; Technical Resources Intl (TRI), Inc, of Bethesda, Maryland; and Rho Federal Systems, Inc., Durham, North Carolina.
• $326 million to Regeneron to support the development of a next-generation monoclonal antibody for COVID-19 prevention.
• $100 million to Global Health Investment Corp. (GHIC), the non-profit organization managing the BARDA Ventures investment portfolio to expand investments in new technologies that will accelerate responses in the future.

• $10 million to Johnson & Johnson Innovation (JLABS) for a competition through Blue Knight, a BARDA-JLABS partnership.

The press release claims that their partnership with Regeneron will help develop a “novel monoclonal antibody that will protect people who do not respond to or cannot take existing vaccines,” despite their attempts to limit the distribution in Florida in 2021.

While Hawaiians are struggling to recover from a devastating fire with an utterly botched governmental response from top to bottom, and our border is wide-open with fentanyl deaths surging, our federal government has allocated $5 billion to fight against COVID-19, which practically no one knew was still a “thing”.